April 2009 Drug Protein Targets
claudin 3
Claudin-3 (CLDN3) is a tight junction protein overexpressed in 90% of ovarian tumours. Overexpression promotes migration, invasion and increased survival of ovarian cancer cells. It is also a low-affinity receptor for Clostridium perfringens enterotoxin.
- Alnylam is developing a small interfering RNA against claudin-3, for the treatment of ovarian cancer. It also has potential in other claudin-3-overexpressing tumours such as breast and prostate cancers.
- CLDN3 belongs to the Receptor Target Family Group. Its Entrez Gene ID is 1365.
chemokine (C-X-C motif) ligand 16
More commonly referred to as CXCL16, both membrane-bound and soluble forms of this protein are produced. It is expressed in T-cell areas and has been shown to mediate chemotaxis and the adhesion of activated T-cells via the chemokine receptor CXCR6. Calcium mobilization has also been demonstrated.
- CoGenesys is developing a MAb against CXCL16 for the treatment of inflammation in tissues including liver, lung, CNS, joint synovium and vasculature.
- CXCL16 belongs to the Cytokine/Growth factor > Cytokine > Chemokine Target Family Group. Its Entrez Gene ID is 58191.
CD200 receptor 1
Expressed in granulocytes, monocytes, most T-cells, NK-cells and B-cells, CD200 receptor 1 (CD200R1) is the receptor for the CD200/OX2 cell-surface glycoprotein. Interaction with CD200 may result in a myeloid downregulatory signal.
- CoGenesys is developing a MAb against CD200R1, for the treatment of rheumatoid arthritis, transplant rejection and autoimmune diseases. It also has potential in the treatment of asthma and allergy.
- CD200R1 belongs to the Receptor Target Family Group. Its Entrez Gene ID is 131450.
tripartite motif-containing 37
This member of the TRIM family, commonly referred to as TRIM37, is incorporated into HIV-1 particles and interferes with HIV-1 reverse transcription by physical interaction with reverse transcriptase. Mutations in TRIM37 are associated with mulibrey nanism, an autosomal recessive disorder prevalent in Finland.
- Myriad Genetics is investigating the use of therapeutics based on TRIM37 as anti-HIV antivirals.
- Its Entrez Gene ID is 4591.
killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1
The killer cell immunoglobulin-receptor (KIR) family of proteins are classified by the number of extra-cellular immunoglobulin domains they contain and whether they have a long or short cytoplasmic tail. They have been shown to act as receptors on natural killer cells for HLA-C alleles. They inhibit natural killer cell activity thus preventing cell lysis. This KIR is commonly referred to as KIR2DL1.
- IPH-2101 is a fully-human anti-KIR IgG4 MAb, under development by Innate Pharma for the treatment of onco-haematological conditions.
- KIR2DL1 belongs to the Receptor Target Family Group. Its Entrez Gene ID is 3802.
killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2
This member of the KIR family is also known as KIR2DL2.
- IPH-2101 is a fully-human anti-KIR IgG4 MAb, under development by Innate Pharma for the treatment of onco-haematological conditions.
- KIR2DL2 belongs to the Receptor Target Family Group. Its Entrez Gene ID is 3803.
killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3
This member of the KIR family is also known as KIR2DL3.
- IPH-2101 is a fully-human anti-KIR IgG4 MAb, under development by Innate Pharma for the treatment of onco-haematological conditions.
- KIR2DL3 belongs to the Receptor Target Family Group. Its Entrez Gene ID is 3804.
killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2
This member of the KIR family is also known as KIR3DL2.
- IPH-4101 is a fully-human anti-KIR IgG4 MAb, under development by Innate Pharma for the treatment of onco-haematological conditions.
- KIR3DL2 belongs to the Receptor Target Family Group. Its Entrez Gene ID is 3812.
Pharmaprojects - New protein targets for drug development
© Informa UK Ltd 2008
Registered Office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK.
Registered in England and Wales No: 1072954
